Vertebroplasty for the Treatment of Fractures Due to Osteoporosis

Mayo Clinic

Status and phase: Completed; Phase 3

Conditions: Osteoporosis; Spinal Fractures

Treatments: Procedure: Sham vertebroplasty; Device: Percutaneous vertebroplasty

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00068822

R01AR049373 (U.S. NIH Grant/Contract)

UL1RR025014 (U.S. NIH Grant/Contract)

NIAMS-096

1912-03

Details and patient eligibility

About

Vertebroplasty is a procedure used to stabilize broken vertebrae, the bones that form the spine. This study will evaluate the effectiveness of vertebroplasty for the treatment of fractures due to osteoporosis.

Full description

Spontaneous, atraumatic compression fractures due to osteoporosis occur in more than 700,000 patients per year. Pain associated with these fractures may be excruciating, but before the advent of percutaneous vertebroplasty, treatment options were limited. Analgesic medications, bed rest, and bracing have been the mainstays of treatment, but each of these therapies has substantial limitations.

Because of the dearth of viable treatment options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have not accounted for numerous important potential biases, including the natural tendency for compression fractures to heal spontaneously, regression toward the mean (wherein patients seek medical attention when pain is maximum), and the placebo effect. This study will examine the clinical efficacy of percutaneous vertebroplasty for treatment of painful osteoporotic vertebral compression fractures.

Participants in this study will be randomly assigned to receive either percutaneous vertebroplasty or a sham procedure (placebo control group). Participants may have up to 2 spinal levels treated. Participants will be enrolled in the study for 1 year and will have study visits at entry and Months 1 and 12. There will also be phone visits at Days 1, 2, 3, and 14 and Months 3 and 6. After Month 1, crossover from the placebo group to the vertebroplasty group will be allowed.

Enrollment: 131 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed osteoporosis or osteopenia by a referring physician and/or medical history and physical exam OR osteopenia on plain film
• Vertebral compression fracture in vertebrae T4 through L5, of less than 1 year old
• Pain not responsive to standard medical therapy
• Current rating for pain intensity of at least 3 on a scale of 0 to 10

Exclusion criteria

• Evidence or suspicion of malignant tumor or spinal canal compromise
• Concomitant hip fracture
• Local or systemic infection
• Uncorrectable bleeding diatheses
• Surgery within the previous 60 days
• Lack of access to telephone
• Inability to communicate in English
• Dementia
• Pregnancy
• Abnormal renal function or anticipated venography
• Conscious sedation is contraindicated for subject

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

131 participants in 2 patient groups, including a placebo group

Vertebroplasty

Experimental group

Description:

Participants will receive percutaneous vertebroplasty

Treatment:

Device: Percutaneous vertebroplasty

Control Group

Placebo Comparator group

Description:

Participants will receive sham vertebroplasty without PMMA

Treatment:

Procedure: Sham vertebroplasty